BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 8501492)

  • 1. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.
    Yahalom J; Gulati SC; Toia M; Maslak P; McCarron EG; O'Brien JP; Portlock CS; Straus DJ; Phillips J; Fuks Z
    J Clin Oncol; 1993 Jun; 11(6):1062-70. PubMed ID: 8501492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.
    Yahalom J; Gulati S
    Ann Oncol; 1991 Feb; 2 Suppl 2():67-71. PubMed ID: 2049322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease.
    Yahalom J; Gulati S; Shank B; Clarkson B; Fuks Z
    Int J Radiat Oncol Biol Phys; 1989 Nov; 17(5):915-22. PubMed ID: 2478511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.
    Gulati S; Yahalom J; Acaba L; Reich L; Motzer R; Crown J; Toia M; Igarashi T; Lemoli R; Hanninen E
    J Clin Oncol; 1992 Jun; 10(6):936-41. PubMed ID: 1588372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
    Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
    Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
    J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Evens AM; Altman JK; Mittal BB; Hou N; Rademaker A; Patton D; Kaminer L; Williams S; Duffey S; Variakojis D; Singhal S; Tallman MS; Mehta J; Winter JN; Gordon LI
    Ann Oncol; 2007 Apr; 18(4):679-88. PubMed ID: 17307757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease.
    Tourani JM; Levy R; Colonna P; Desablens B; Leprise PY; Guilhot F; Brahimi S; Belhani M; Ifrah N; Sensebe L
    J Clin Oncol; 1992 Jul; 10(7):1086-94. PubMed ID: 1607915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
    Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease.
    Jones RJ; Piantadosi S; Mann RB; Ambinder RF; Seifter EJ; Vriesendorp HM; Abeloff MD; Burns WH; May WS; Rowley SD
    J Clin Oncol; 1990 Mar; 8(3):527-37. PubMed ID: 2307990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
    Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
    Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
    Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
    Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
    J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive therapy and autotransplantation in Hodgkin's disease.
    Reece DE; Phillips GL
    Stem Cells; 1994 Sep; 12(5):477-93. PubMed ID: 7804123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.